Not finding it? Sign in to also search OpenAlex live.
-
Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
Sarah Gillessen, Andreas Hüttmann, Vladan Vučinić, Horst Müller, Annette Plütschow, Andreas Viardot, +13 more
5citations -
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry2022 Journal of Cancer Research and Clinical Oncology article Medicine Acute Myeloid Leukemia Research Open access
Maher Hanoun, Leo Ruhnke, Michael Krämer, Christine Hanoun, Kerstin Schäfer‐Eckart, Björn Steffen, +27 more
10citations -
Concanavalin A staining: a potential biomarker to predict cytarabine sensitivity in acute myeloid leukemia2024 Frontiers in Hematology article Biochemistry, Genetics and Molecular Biology Glycosylation and Glycoproteins Research Open access
Tao Zhang, Glenn Marsman, Diego A. Pereira‐Martins, Manfred Wuhrer, Gerwin A. Huls, Valerie R. Wiersma
1citations -
Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, +29 more
7citations -
Rationale and Design of GnG-Trial: A Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Double-Blinded Intensive Postremission Therapy with or Without Glasdegib in Older Patients with Newly Diagnosed AML
Sonia Jaramillo, Johannes Krisam, Lucian Le Cornet, Markus Kratzmann, Lukas Baumann, Tim Sauer, +28 more
0citations -
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Sonia Jaramillo Segura, Maxi Wass, Judith Schaffrath, Kathrin Rieger, Axel Nogai, Mathias Haenel, +46 more
5citations -
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva‐Maria Wagner‐Drouet, Lutz Peter Müller, Christoph Schmid, +62 more
53citations -
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study
Jacoline E. C. Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C. Minnema, +14 more
25citations -
Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial
Christoph Röllig, Björn Steffen, Nael Alakel, Regina Herbst, Richard Noppeney, Maher Hanoun, +32 more
5citations -
S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY (“3 + 7”) FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG
M Lübbert, P. W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, +26 more
3citations -
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Michael Lübbert, Pierre W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, +29 more
2citations